Compare BRFH & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRFH | BTAI |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.7M | 49.2M |
| IPO Year | N/A | 2018 |
| Metric | BRFH | BTAI |
|---|---|---|
| Price | $3.20 | $2.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $32.80 |
| AVG Volume (30 Days) | 6.3K | ★ 658.3K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,574,000.00 | $752,000.00 |
| Revenue This Year | $37.56 | N/A |
| Revenue Next Year | $101.44 | $544.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.49 | N/A |
| 52 Week Low | $2.00 | $1.17 |
| 52 Week High | $6.08 | $9.26 |
| Indicator | BRFH | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 48.61 | 51.76 |
| Support Level | $3.28 | $1.82 |
| Resistance Level | $3.44 | $2.33 |
| Average True Range (ATR) | 0.13 | 0.17 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 39.39 | 62.87 |
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.